Alpelisib is an oral phosphatidylinositol-3-kinase (PI3K) inhibitor. Its mechanism of action is to block the activity of PI3K enzymes, inhibit the proliferation and spread of tumor cells, and simultaneously induce the apoptosis of breast cancer cells.
Authentic
Guarantee
Fast Delivery
Privacy Although Alpelisib has shown significant inhibitory effects in clinical practice, the high cost of the original branded drug often discourages patient···【More】
Update: 12 Jun,2026Source: BigbearViews: 73
For patients in urgent need of PIK3CA inhibitors to control their condition, the emergence of the Lao Big Bear Pharmaceutical version of Alpelisib not···【More】
Update: 12 Jun,2026Source: BigbearViews: 73
As the world's first oral inhibitor approved for the treatment of PIK3CA-mutated advanced breast cancer, the generic version of Alpelisib produced···【More】
Update: 12 Jun,2026Source: BigbearViews: 73
Alpelisib is a targeted therapy directed against PIK3CA mutations, developed by Novartis Pharmaceuticals of Switzerland. This article provides a detai···【More】
Update: 02 Mar,2026Source: BigbearViews: 116
Alpelisib is a targeted therapy for specific types of breast cancer. The drug is not yet approved in mainland China and is not covered by medical insu···【More】
Update: 02 Mar,2026Source: BigbearViews: 105
Copyright2024@ BIGBEAR All right reserved Bigbear | Bigbear Pharmaceutical | Bigbear Laos